Dr. Shrader has 26 years of experience in the pharmaceutical industry. During the last 14 years, he has led teams that have advanced 3 drugs into the clinic for neurodegenerative diseases. These drugs have completed phase 2 clinical trials in Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Friedriech’s ataxia (FA), Rett Syndrome, and Leigh Syndrome. For one of these drugs, Vatiquinone™, Dr. Shrader led a team which in 20 months and $5M, went from the discovery of that drug, to its first dose in a 4-year old girl with Leigh’s syndrome. Dr. Shrader has also successfully led a team for the development of clinical biomarkers for a phase 2 ALS trial, demonstrating target engagement.